Accessibility Menu
Viva Biotech logo

Viva Biotech(OTC) VBIZF

Market Cap$335.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-71%
5 Year-83%
1 Year-15%
1 Month+20%
$0.16
+0.00%
+0.00Today
Viva Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.162026-07-30
Viva Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.162026-07-01
1 month+19.72%USD 0.132026-06-16
3 month-52.97%USD 0.342026-04-17
Year to date-16.71%USD 0.192025-12-29
1 year-14.55%USD 0.192025-07-29
3 year-23.92%USD 0.212023-07-17
5 year-83%USD 0.952021-07-30
Since inception-71.42%USD 0.572019-09-25

Viva Biotech Financials at a Glance

Market Cap

$335.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.70B

Net Income (TTM)

CN¥385.43M

EPS (TTM)

$0.01

P/E Ratio

11.14

Dividend

$0.00

Beta (Volatility)

-1.47 (Low)

Price

$0.16

Volume

2,500

Open

$0.16

Previous Close

$0.16

Daily Range

$0.16 - $0.16

52-Week Range

$0.13 - $0.43

Estimated Earnings Date

Aug 31, 2026

VBIZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viva Biotech

Viva Biotech Holdings is an investment holding enterprise specializing in comprehensive drug discovery services for biotechnology and pharmaceutical clients globally. The company employs a structure-based approach to facilitate the identification and development of promising drug candidates.

Products and Services
  • Discovery biology services, including protein expression and purification
  • Advanced chemistry services, such as medicinal and synthetic chemistry
  • Contract development and manufacturing (CDMO) for small molecule active pharmaceutical ingredients (APIs)
Growth Outlook
  • Revenue increased to CNY 882.67 million in Q4 2025, showing strong demand
  • Net income reached CNY 96.33 million in Q4 2025, indicating profitability
  • TTM gross profit margin stands at 37.91%, reflecting operational efficiency
Financial Highlights
  • Operating income of CNY 76.16 million in Q4 2025, showcasing solid operational performance
  • Current ratio of 1.50, indicating good short-term financial health
  • Net income margin of 10.91% in Q4 2025, demonstrating effective cost management
Viva Biotech Holdings has established itself as a key player in the biotechnology sector, providing essential services that support drug discovery and development. The company's diverse offerings, including advanced chemistry and biology services, position it well to capitalize on the growing demand for innovative therapeutics. Recent financial performance highlights a robust growth trajectory, with significant increases in revenue and net income, underscoring the company's operational efficiency and market potential. The strong current ratio further indicates a solid financial foundation, making Viva Biotech an intriguing option for investors interested in the biotechnology industry.
AI Generated • Aug 1, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

2,169

CEO

Chen Mao

Website

www.vivabiotech.com

Headquarters

Shanghai, SH 201318, CN

VBIZF Financials

Key Financial Metrics (TTM)

Gross Margin

37.91%

Operating Margin

11.17%

Net Income Margin

12.71%

Return on Equity

5.57%

Return on Capital

3.53%

Return on Assets

3.05%

Earnings Yield

8.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$335.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

2.50K

Avg. Volume

1.25K

Financials (TTM)

Gross Profit

CN¥1.34B

Operating Income

CN¥421.63M

EBITDA

CN¥825.46M

Operating Cash Flow

CN¥596.02M

Capital Expenditure

-CN¥312.73M

Free Cash Flow

CN¥283.29M

Cash & ST Invst.

CN¥1.13B

Total Debt

CN¥1.33B

Viva Biotech Performance Analysis

Viva Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 353,390,5688.3%
20232023-12-31CNY 304,244,079-13.9%
20242024-12-31CNY 276,045,763-9.3%
20252025-12-31CNY 240,586,839-12.8%
Viva Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-3.1%
Q42024-12-312.3%
Q22025-06-30-17.2%
Q42025-12-316.1%
Viva Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.04N/A
20232023-12-31CNY -0.02-50.7%
20242024-12-31CNY 0.01N/A
20252025-12-31CNY 0.0161.7%
Viva Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30199.6%
Q42024-12-31-67.0%
Q22025-06-30177.8%
Q42025-12-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥882.67M

-12.9%

Gross Profit

CN¥310.88M

-6.5%

Gross Margin

35.22%

N/A

Market Cap

$335.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$154.48K

N/A

Employees

2,169

N/A

Net Income

CN¥96.33M

+182.2%

EBITDA

CN¥178.05M

+9.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥1.13B

+9.2%

Total Debt

CN¥1.33B

-30.1%

Accounts Receivable

CN¥630.06M

+54.7%

Inventory

CN¥335.91M

+29.3%

Long Term Debt

CN¥358.42M

-62.3%

Short Term Debt

CN¥972.83M

+2.1%

Return on Assets

3.05%

N/A

Return on Invested Capital

3.34%

N/A

Free Cash Flow

CN¥44.98M

+323.6%

Operating Cash Flow

CN¥92.21M

+39.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLVSFCellaVision AB (publ)
$14.00+0.00%
PTCHFPureTech Health plc
$1.53+0.00%
INRLFValneva SE
$2.43+0.00%
SOLTFNxera Pharma Co., Ltd.
$5.73+1.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About VBIZF

What is the current price of Viva Biotech?

Viva Biotech is trading at $0.16 per share.

What is the 52-week range for Viva Biotech?

Over the past 52 weeks, Viva Biotech has traded between $0.13 and $0.43.

How much debt does Viva Biotech have?

As of the most recent reporting period, Viva Biotech reported total debt of CN¥190.41M.

How much cash does Viva Biotech have on hand?

Viva Biotech reported CN¥155.80M in cash and cash equivalents in its most recent financial results.

What is Viva Biotech’s dividend yield?

Viva Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services